ESR1 and breast cancer: In the Symmans 2 and Loi breast cancer datasets [33, 34], estrogen receptor (ER)-positive breast cancer patients with metastatic events at both 3 and 5 years expressed lower levels of EI24 compared with their non-metastatic counterparts (Figure 6E, Supplemental Figure 6A).